CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2, Open Label Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K Dual δ/γ Inhibitor, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04204057
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:17.632381+00:00
Published At: 2021-07-22T00:00:00+00:00
Record Updated At: 2024-08-13
Results Posted At: 2021-07-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Leukemia, Lymphocytic, Chronic, B-Cell"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-08-13"
protocolSection.identificationModule.nctId: "NCT04204057"
protocolSection.identificationModule.officialTitle: "A Phase 2, Open Label Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K Dual \u03b4/\u03b3 Inhibitor, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2021-07-22"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.